Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-3424 in AKR1C3-high advanced hepatocellular carcinoma after ICI failure
NCT07310173Phase 2Recruiting
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of odafosfamide in hepatocellular carcinoma (HCC) (3 arms), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoint: 9-month Overall Survival Rate. Started Jan 2026; status: recruiting.
02
Drugs
odafosfamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07310173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310173.